Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11887852 | 0.88 | FFAR1 (0.75) | APEX1FFAR1ALDH1A1CXCL12MEN1 | |
| SCHEMBL11214282 | 0.83 | SMN1; SMN2 (0.50) | APEX1FFAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL11214281 | 0.83 | APEX1 (0.46) | APEX1FFAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL29650224 | 0.83 | SMN1; SMN2 (0.50) | APEX1FFAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL19309449 | 0.82 | MEN1 (0.56) | APEX1FFAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL22714458 | 0.81 | ALDH1A1 (0.53) | APEX1FFAR1ALDH1A1CA12CA2 | |
| SCHEMBL21102985 | 0.80 | APEX1 (0.44) | APEX1FFAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL6089528 | 0.79 | APEX1 (0.64) | APEX1FFAR1ALDH1A1CXCL12MEN1 | |
| SCHEMBL8870413 | 0.79 | APEX1 (0.64) | APEX1FFAR1ALDH1A1CXCL12MEN1 | |
| SCHEMBL4278929 | 0.79 | APEX1 (0.64) | APEX1FFAR1ALDH1A1CXCL12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046736-B1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2019-06-12 | — | — | EP | claimed |
| EP-2046736-B1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180334430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2018-11-22 | — | — | US | disclosed |
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20090258817-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK A/S (DK) | 2009-10-15 | — | — | US | disclosed |
| US-20090258817-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK A/S (DK) | 2009-10-15 | — | — | US | disclosed |
| US-20090258817-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK A/S (DK) | 2009-10-15 | — | — | US | disclosed |
| WO-2008014430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1147085-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | WYETH CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | WYETH | 2004-11-18 | — | — | US | disclosed |
| US-6753337-B2 | INHIBITORS OF TNF-ALPHA CONVERTING ENZYME; TREATMENT OF ARTHRITIS, INFLAMMATION, INFLAMMATORY BOWEL DISEASE ETC, | WYETH HOLDINGS CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | AMERICAN CYANAMID COMPANY | 2002-07-04 | — | — | US | disclosed |
| US-6358980-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | MMP17, MMP1, MMP9 | APEX1 333/4885FFAR1 1160/4885ALDH1A1 1065/4885 |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | MMP17, MMP1, MMP9 | APEX1 333/4885FFAR1 1160/4885ALDH1A1 1065/4885 |
| US-20090258817-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB7, ABCB4, PAICS | APEX1 1540/4885FFAR1 3201/4885ALDH1A1 1627/4885 |
| US-20180334430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB7, ABCB4, PAICS | APEX1 1540/4885FFAR1 3201/4885ALDH1A1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.